Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Hoffmann-La Roche
Eli Lilly and Company
Eli Lilly and Company
Inhibrx Biosciences, Inc
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Revolution Medicines, Inc.
Poseida Therapeutics, Inc.
Atara Biotherapeutics
Hoffmann-La Roche
Revolution Medicines, Inc.
Blueprint Medicines Corporation
Daiichi Sankyo